Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
Study sponsor: Scholar Rock, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-12-18Actual
Enrollment · participants188Actual
Source updated2026-01-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.